Kornimate/medical-research-clean huggingface dataset:
detection of amyloid deposits in the wrist by mri with mapping and high resolution sequences in systemic amyloidosis (amylocarp)

Conditions: Amyloid; Systemic Amyloidosis

Summary: this study is based on the hypothesis that mri could make it possible to non-invasively detect these amyloid deposits at the level of the wrist using parametric sequences known as t1 mapping, in the form of an extension of t1 in the wrists. areas where amyloid deposits are found in the wrist.


Eligibility criteria:
inclusion criteria: patient group: * woman or man over 18 years old * with attr or al cardiac amyloidosis with or without carpal tunnel. the diagnosis of amyloidosis must be proven by a positive myocardial biopsy or diphosphonate scintigraphy. * affiliate or beneficiarie of a social security scheme. * having signed the free and informed consent. healthy volunteers: * woman or man over 18 years old * affiliate or beneficiarie of a social security scheme. * having signed the free and informed consent. exclusion criteria: patient group: * patients participating in another clinical study. * patients suffering from rheumatoid arthritis or other autoimmune disease (vasculitis, lupus, scleroderma, etc.) * patients with a medical history of wrist surgery (exclude the operated side). * patients with a contraindication to performing an mri (pacemaker, etc.) * pregnant or breastfeeding women. * protected patients: adults under guardianship, curatorship or other legal protection, deprived of their liberty by judicial or administrative decision. healthy volunteer: * volunteers participating in another clinical study. * volunteers suffering from rheumatoid arthritis or other autoimmune disease (vasculitis, lupus, scleroderma, etc.) * pregnant or breastfeeding women. * volunteer with a contraindication to performing an mri (pacemaker, etc.) * protected volunteers: adults under guardianship, guardianship or other legal protection, deprived of their liberty by judicial or administrative decision.
efficacy of erlotinib in neoadjuvant setting in patients with stage iiia, n2-positive non-small cell lung cancer

Conditions: Lung Neoplasms; Erlotinib; Neoadjuvant Therapy

Summary: this study propose neoadjuvant chemotherapeutic role by erlotinib.

it is widely accepted that patients with locally advanced non-small cell lung cancer would have better outcome with neoadjuvant therapy followed by surgery than surgery alone. however what should be the standard treatment option is still unclear. erlotinib (tarceva®)is an oral inhibitor of epidermal growth factor receptor (egfr) tyrosine kinase and its anti-neoplastic effect is approved especially women, patients with adenocarcinoma, non-smoker and asian population. moreover if the malignant tissue has egfr mutation, its efficacy is known to be enhanced. so we expect that in those population, patients with locally advanced, n2 positive, erlotinib would be more beneficial than conventional cytotoxic chemotherapy in safety and convenience as neoadjuvant therapy.

Eligibility criteria:
inclusion criteria: * pathologically confirmed n2 positive and stage iiia non-small cell lung cancer * has more than 2 conditions out of following 3 conditions ; adenocarcinoma, non-smoker, women * age ≥ 18 years and ecog performance 0\~1 * has measurable lesion by recist 1.1 * no previous chemotherapy or radiation therapy * adequate organ function by following; anc ≥1,500/ul, hemoglobin ≥9.0g/dl, platelet ≥100,000/ul, pao2 ≥ 60 mmhg, serum cr \ 60 ml/min, serum bilirubin \< 1 x unl, ast (sgot) and alt (sgpt) \< 2.5 x unl, alkaline phosphatase \< 5 x unl * written informed consent form exclusion criteria: * pulmonary carcinoid tumor * previous chemotherapy or radiation therapy * previous history of malignancy within 5 years from study entry except treated non-melanomatous skin cancer or uterine cervical cancer in situ * known allergic history of erlotinib * interstitial lung disease or fibrosis on chest radiogram * active infection, uncontrolled systemic disease (cardiopulmonary insufficiency, fatal arrhythmias, hepatitis) * pregnant or nursing women
major depressive disorder with mixed features - extension

Conditions: Major Depressive Disorder

Summary: lurasidone hcl is a compound that is a candidate for the treatment of major depressive with mixed features.this clinical study is designed to test how well lurasidone works to treat major depressive disorder with mixed features over time.


Eligibility criteria:
inclusion criteria: subject provides written informed consent and is willing and able to comply with the protocol in the opinion of the investigator. subject has completed 6 weeks of treatment in study d1050304 (nct#01421134) or study d1050305 (nct#01423240). subject is judged by the investigator to be suitable for participation in a 12-week clinical trial involving open-label lurasidone treatment and is able to comply with the protocol in the opinion of the investigator. exclusion criteria: subject answers "yes" to "suicidal ideation" item 4 or 5 on the c-ssrs (at time of evaluation) at baseline (day 43 in study d1050304 or d1050305). subject is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.

Keywords: depression lurasidone latuda
the psychology intervention on disease acceptance and quality of life in breast cancer patients

Conditions: Breast Cancer Female

Summary: the psychological rehabilitation of breast cancer patients plays an important role in the whole process of disease rehabilitation. in this paper, patients with breast cancer were treated with act group intervention for a period of four weeks to improve their disease acceptance and psychological flexibility, so as to improve their quality of life. finally, its effect and mechanism are explored by covariance analysis and mediation analysis. the significant findings of this study will provide the quality of life changes in breast cancer patients and how did these changes happen and the moderating role of social support in the process of intervention.

this is a randomized controlled trial that examines the efficacy of brief acceptance and commitment therapy by comparing the differences between act intervention (cases) and waitlist (control). the inclusion criteria are breast cancer patients must be 18 years old and above, early stage of breast cancer (stages 1 to 3), newly diagnosed breast cancer patients in the treatment phase and know about the illness (before and after surgery), have basic writing, reading, and verbal communication skills and volunteer to participate in this study. the exclusion criteria including patients with metastatic or recurrent breast cancer or other malignant tumors, patients had participated act intervention before, patients who were diagnosed with psychoses, substances abuser and people who previously exposed to chemotherapy. respondents will be randomly recruited based on odd and even sequences. those who are in odd sequence will be assigned into group a, and those who are in even sequence will be assigned into group b. it is stipulated that group a is the intervention group and group b is the control group. the respondents will not know in which group that they belong to ensure the single blinding process. breast cancer patients from breast clinic, ippt who met the inclusion criteria will be approached andinformed about the study and procedure will be given. once the respondent agrees to participate, informed consent will be obtained.

Eligibility criteria:
inclusion criteria: * breast cancer patients must be 18 years old and above * early stage of breast cancer (stages 1 to 3) * newly diagnosed breast cancer patients in the treatment phase * know about the illness (before and after surgery) * have basic writing, reading, and verbal communication skills * volunteer to participate in this study exclusion criteria: * breast cancer patients with more than 65 years old * patients with metastatic or recurrent breast cancer or other malignant tumors * patients had participated act intervention before * patients who were diagnosed with psychoses, substances abuser * people who previously exposed to chemotherapy.
massage for pain relief during the active phase of labor

Conditions: Pain

Summary: the objective of this research is to evaluate the effect of massage therapy as a resource for pain relief during the active phase of labor. the research will be of type randomized controlled trial, consisting of low-risk nulliparous pregnant women admitted to the referral center for women's health in ribeirão preto. the mothers will be distributed in two groups (lumbosacral massage) and control (routine maternity) and will be assessed before and after therapy, which corresponds to 30 minutes between 4-5 cm of cervical dilation. the evaluation will be performed by numerical category scale, diagram location of pain and pain questionnaire mcgll (reduced form). after delivery will apply a customer satisfaction questionnaire.

the pain in labor appears as a subjective experience, individual interaction involving a broad physiological, psychosocial and environmental influences, representing one of the main clinical signs of this phase. despite presenting an important biological function, is today well established the need for their relief, since its persistence is associated with harmful effects on mother and fetus. among the available non-pharmacological resources, we highlight the massage therapy that has shown positive effects in relieving pain and promoting the comfort of the mother. the objective of this research is to evaluate the effect of massage therapy as a resource for pain relief during the active phase of labor. the research will be of type randomized controlled trial, consisting of low-risk nulliparous pregnant women admitted to the referral center for women's health in ribeirão preto. the mothers will be distributed in two groups (lumbosacral massage) and control (routine maternity) and will be assessed before and after therapy, which corresponds to 30 minutes between 4-5 cm of cervical dilation. the evaluation will be performed by numerical category scale, diagram location of pain and pain questionnaire mcgll (reduced form). after delivery will apply a customer satisfaction questionnaire. after collecting the data, the groups are statistically analyzed using the linear regression model with mixed effects (fixed and random), taking into account a value of p \<0.05 to obtain the statistical significance of 5%.

Eligibility criteria:
inclusion criteria: * nulliparous * literate * a single fetus in vertex position * low-risk pregnancy * from 37 weeks of gestation * cervical dilatation from 4 cm with normal uterine dynamics in this phase * labor in early spontaneous * no use of medications during the study period * absence of cognitive or psychiatric problems * intact membranes * no risk factors associated * you want to participate and signing the informed consent exclusion criteria: * use of drugs or any procedure that aims to relieve pain * intolerance to the application of massage therapy * presence of dermatological conditions that indicate against the application of massage therapy

Keywords: labor pain massage
improving primary spontaneous pneumothorax (psp) treatment techniques in vats

Conditions: Pneumothorax; Pleurodesis

Summary: the purpose of this study is to: 1. evaluate the validity of using abnormal characteristics of the pneumothorax line, as evaluated from chest x-ray film, as the operative indications for video-assisted thoracic surgery (vats) on primary spontaneous pneumothorax (psp). 2. through a randomized double blind controlled trial on patients whose psp was caused by lung bullae, evaluate the effectiveness of pleurodesis in terms of the rate of recurrence of psp and the trauma of the operation on patients. 3. based on the findings, establish selection standards for the timing of surgery to treat psp by vats and establish technical specifications for performing operations on different types of lung bullae. the goal is to improve the diagnosis and treatment of psp so as to reduce the recurrence rate of pneumothorax, reduce the trauma of operation, shorten hospital stays and postoperative recovery time, and provide better services for returning to everyday life and improving the quality of life for patients.


Eligibility criteria:
inclusion criteria: 1. patients in whom obvious bullous forms are seen in psp pneumothorax lines, or whose pneumothorax lines are rough and interrupted with or without thoracentesis, thoracic close drainage 2. patients whose lung compression exceeded 30% for the first incidence of pneumothorax 3. patients between the ages of 14 and 40, with normal vital signs (body temperature, breathing, blood pressure, pulse) and normal results on routine examination (routine blood test, liver and kidney functions) 4. no language barrier, such as surdimutism, aphasia 5. patients who voluntarily joined the group and signed the informed consent after reviewing the substance, significance and risks of this experiment exclusion criteria: 1. patients who refuse vats operation 2. patients who refuse the follow-up 3. patients with secondary spontaneous pneumothorax including that caused by emphysema, copd, asthma, pulmonary lymphangiomyomatosis, thoracic injury and other diseases 4. patients with mental illness, low iq, or inability to understand the informed consent 5. substance abusers

Keywords: primary spontaneous pneumothorax vats pleurodesis recurrence rate
improving keloids using targeted ultraviolet-b irradiation

Conditions: Keloid

Summary: treatment of keloids with targeted ultraviolet-beta (uvb) radiation will improve the clinical appearance and induration of lesions.


Eligibility criteria:
inclusion criteria: * participants must be 18 years old or over * participants must have a diagnosis of keloid * no treatment with topical or intralesional steroids for 1 month prior to study exclusion criteria: * patients who are unable to provide informed consent * a history of photosensitivity, lupus erythematosus, porphyria or current use of a known photosensitizing drug * unwillingness to stop with topical or intralesional steroids for 1 month prior to study * a history of malignant melanoma * a history of radiation therapy to area of interest * subjects who self-report that they are pregnant or nursing
exploring central sensitization in pregnant women

Conditions: Pelvic Girdle Pain; Chronic Pain

Summary: pelvic girdle pain (pgp) is reported by 50% of pregnant women and up to 11 years after pregnancy, 10% of women have persistent and per definition chronic pgp. central (nervous system) sensitization that elicits pain hypersensitivity, may be one explanation. the overall aim of this study is to explore features of central sensitization in pregnant women and its predictive ability on physical activity, functioning and health in women with pgp. measurements of central sensitization will be done on two study groups, pregnant women with pgp and healthy controls. to identify women at risk to develop chronic pain in relation to a common pain experience ie pgp in pregnancy, may help us understand if central sensitization early in life explains why women develop chronic pain.

pelvic girdle pain (pgp) is reported by 50% (60000) of pregnant women yearly in sweden. pgp is expected to disappear after delivery. however up to 11 years after pregnancy, 10% of women have persistent and per definition chronic pgp with large impact on their physical activity, functioning,and health. central (nervous system) sensitization, defined as an amplification of neural signaling within the central nervous system that elicits pain hypersensitivity, may be one explanation why 10% of women develop postpartum chronic pgp and related physical inactivity. the overall aim of this study is to explore features of central sensitization in pregnant women and its predictive ability on physical activity, functioning and health in women with pgp. two study groups, pregnant women with pgp and healthy controls (including non-native swedish) will be included through maternity care units and a blog. measurements of primary outcome central sensitization will be done. to identify women at risk to develop chronic pain in relation to a common pain experience ie pgp in pregnancy, may help us understand if central sensitization early in life explains why women develop chronic pain.

Eligibility criteria:
inclusion criteria: * pregnant (first time pregnant or previous experience of pregnancy) * 18 years of age or older * have a single foetus pregnancy * be in gestational weeks 20-30 * able to read and understand swedish or english exclusion criteria: * no history of a fracture or malignant disease in the back, pelvis, pelvic floor or hips * no systemic disease of the musculoskeletal or the nervous system * no diseases such as gestational diabetes or diabetes type 1 and 2, hypertension * no obstetric complications * no contradiction for tests.
metformin for treatment antipsychotic induced amenorrhea in female schizophrenic patients

Conditions: Amenorrhea

Summary: antipsychotics such as risperidone could induce amenorrhea in schizophrenic patients. the investigators conducted a randomized, placebo-controlled study to test the efficacy of metformin for antipsychotic induced amenorrhea in schizophrenia patients.


Eligibility criteria:
inclusion criteria: * schizophrenia patient * amenorrhea for more than three months after antipsychotic treatment exclusion criteria: * liver or renal diseases * pregnant or lactating women * cardiovascular diseases * hypertension or diabetes mellitus
reducing childhood hearing loss in an alaska native population through a new school screening and referral process that utilizes mobile health and telemedicine

Conditions: Hearing Loss

Summary: hearing loss is a common health problem in alaska. up to 75% of children growing up in alaskan villages experience frequent ear infections, one of the major treatable causes of hearing loss. children with even mild hearing loss face many challenges. these children often experience speech and language delays and have trouble in school. teens with hearing loss are more likely to drop out of school, and are at risk for having difficulty finding jobs as adults. promptly diagnosing and treating hearing loss is important for preventing these consequences. alaska mandates school-based hearing screening, but many children with hearing loss are not identified by the current screening protocol, and most who are referred never make it into the healthcare system for diagnosis and treatment. alaska has already developed innovative strategies to address hearing loss. a network of village health clinics staffed by community health aides provide local care, and telemedicine has been adopted in over 250 village clinics statewide. despite being widely available, telemedicine has not yet been used in school hearing screenings to speed up the referral process. norton sound health corporation has partnered with duke and johns hopkins universities to explore whether a new school screening and referral process that incorporates mobile, or mhealth, screening and telemedicine referral will reduce childhood hearing loss disparities in the norton sound region. children from kindergarten through 12th grade in 15 norton sound villages will receive the current school screening protocol and the new mhealth screen. villages will then be randomized to continue the current primary care referral process or to adopt telemedicine referral for school screenings. the investigators hypothesize that the new mhealth screening protocol will identify more children with hearing loss, and telemedicine referral will reduce time to diagnosis. by better identifying hearing loss and speeding up diagnosis and treatment, the investigators expect the burden of childhood hearing loss to drop, hearing-related quality of life to improve, and school performance to improve in villages with telemedicine referral compared to current primary care referral villages. if the study shows these positive effects, mhealth screening and the telemedicine referral process could be implemented in school districts across the state of alaska to reducing childhood hearing loss disparities statewide.


Eligibility criteria:
inclusion criteria: * student of the bering strait school district (bssd) in alaska * all school-aged children, from kindergarten through 12th grade in the school district are eligible to participate * parental signed consent to undergo routine hearing screening in the school setting * verbal assent from children enrolled in the study exclusion criteria: * not a student of the bering strait school district * parental consent for routine hearing screening not obtained * verbal assent not obtained
study of risk factors and genetic association with bortezomib-induced peripheral neuropathy in multiple myeloma

Conditions: Multiple Myeloma

Summary: background and objective the introduction of a proteasome inhibitor bortezomib has significantly improved response rates and overall survival in patients with multiple myeloma (mm), and it has soon become the cornerstone of treatment in both newly diagnosed and relapsed/refractory settings. however, the incidence of peripheral neuropathy related to bortezomib (bipn) is unignorable and which becomes an obstacle during treatment with bortezomib, either alone or in combination. until now, there are no consistent findings regarding the risk factors that may cause bipn. there is either lack of large scale study of bipn in taiwan. this study aims to clarify risk factors of bipn using retrospective analysis in a large cohort with longer observation period as well as the relations between bipn and gene polymorphisms, and to compare different routes in the incidence of bipn. methods this is a retrospective cohort study with a sample size of about 400 mm patients treated ever with at least one full cycle of bortezomib in the institution. all the patients enrolled need to be adults (≧20 years ) with measurable m-component in either blood or urine. the investigators will perform a retrospective chart review to collect clinical data, including anti-mm and concomitant medications, to evaluate the incidence and severity of bipn in this cohort, as well as any meaningful risk factors contributed to bipn. the investigators also plan to perform genotyping for the possible genetic factors associated with development of bipn. expected contributions the successful collaboration between clinical hematologist-oncologist and biopharmaceutical researcher would result in the concrete evidence of efficacy and safety of bortezomib in taiwanese patients with mm. the findings in this large cohort study will unveil the risk factors of bipn, including the administration routes and ethnicity. as results, the investigators would be able to provide the precision medicine-based bortezomib treatment strategy to mm patients in taiwan.


Eligibility criteria:
inclusion criteria 1. age \>20 years 2. diagnosed with mm 3. bortezomib new users (2006/4/1-2016/6/30) exclusion criteria 1. varying on iv and sc administration 2. receive bortezomib at other hospitals

Keywords: multiple myeloma peripheral neuropathy subcutaneous injection bortezomib risk factors